Core Viewpoint - Guichuang Tongqiao (02190) has issued a positive profit forecast for the year 2025, expecting a significant increase in net profit and revenue compared to the previous year [1][4]. Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1][4]. - Revenue is expected to surpass RMB 1.05 billion, with a year-on-year increase of about 34.6% [1][4]. Business Drivers - The strong performance is attributed to robust sales growth of core products, accelerated development of overseas business, and continuous optimization of operational efficiency [1][4]. - Key products such as the Tongqiao Qilin™ blood flow guiding device, neurovascular guide wires, UltraFree® drug-eluting PTA balloon dilatation catheters, and ZYLOX Swan® venous RF closure catheters have all seen rapid revenue growth [1][4]. International Market Expansion - The company's overseas market sales revenue has more than doubled year-on-year, with increasing penetration rates in key markets such as Germany, France, and Italy [1][4].
归创通桥盘中涨超5% 预期2025年度净利润同比大幅增长约139.4%